New Zealand - English - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - ibuprofen 400mg;  ;   - coated tablet - 400 mg - active: ibuprofen 400mg     excipient: acacia carmellose sodium colloidal silicon dioxide croscarmellose sodium macrogol 6000 opacode red s-1-15094 purified talc sodium citrate sodium laurilsulfate stearic acid sucrose titanium dioxide - nurofen 400 double strength is indicated for the temporary relief of pain and /or inflammation associated with headache, migraine headache, tension headache, sinus pain, dental pain, backache, muscular aches and pains, period pain, sore throat, arthritic pain, colds and flu symptoms. reduces fever.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 400mg;  ;   - tablet - 400 mg - active: amisulpride 400mg     excipient: hypromellose   lactose monohydrate macrogol stearate 2000 magnesium stearate microcrystalline cellulose powdered cellulose sodium starch glycolate titanium dioxide - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin - solution for infusion - 400 mg - active: moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - avelox tablets and solution for infusion is indicated for the treatment of the following bacterial infections caused by susceptible strains: · complicated intra-abdominal infections including polymicrobial infections such as abscesses

United States - English - NLM (National Library of Medicine)

honeywell safety products usa, inc - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - eyewash - for flushing the eye to remove loose foreign material, air pollutants or chlorinated water first aid antiseptic - first aid to help prevent infection in minor cuts, scrapes, and burns pain reliever/ fever reducer - temporarily relieves minor aches and pains due to the common cold and headache - temporarily reduces fever keep out of reach of children. first aid antibiotic - first aid to help prevent infection in - minor cuts - scrapes - burns - in the eyes - over large areas of the body first aid antiseptic - first aid to help prevent infection in minor cuts, scrapes and burns benzethonium chloride 0.2% w/w benzocaine 10% w/w menthol 0.33% w/w for the temporary relief of pain and itching and helps protect against infection in: - minor cuts and scrapes - burns - sunburn - insect bites - minor skin irritations antiseptic handwash - for hand washing to decrease bacteria on skin - recommended for repeated use

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al ittihad drug store france - 400 ml vial - infusion - 20 g/400 ml - immunologicals , vaccines-immunoglobulins

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية لإنتاج الأدوية - jordan pharmaceutical manufacturer (jpm) - gabapentin 400 mg - 400 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - imatinib, quantity: 400 mg (equivalent: imatinib mesilate, qty 478 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; magnesium stearate; purified talc; macrogol 4000; iron oxide red; iron oxide yellow - glivec is indicated for the: -treatment of patients with chronic myeloid leukaemia (cml). -treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. -treatment of adult patients with relapsed or refractory ph+ all as monotherapy. -treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed. -treatment of adult patients with aggressive systemic mastocytosis (asm) where conventional therapies have failed. treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). -treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) -adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - imatinib mesilate, quantity: 477.877 mg (equivalent: imatinib, qty 400 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - 1) imatinib-teva (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (cml). 2) imatinib-teva (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. 3) imatinib-teva (imatinib) is indicated for the treatment of adult patients with relapsed or refractory ph+all as monotherapy. 4) imatinib-teva (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene rearrangements, where conventional therapies have failed. 5) imatinib-teva (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed. 6) imatinib-teva (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). 7) imatinib-teva (imatinib) is indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) 8) imatinib-teva (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist. 9) imatinib-teva (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - imatinib mesilate, quantity: 477.877 mg (equivalent: imatinib, qty 400 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - 1) imatinib-teva (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (cml). 2) imatinib-teva (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. 3) imatinib-teva (imatinib) is indicated for the treatment of adult patients with relapsed or refractory ph+all as monotherapy. 4) imatinib-teva (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene rearrangements, where conventional therapies have failed. 5) imatinib-teva (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed. 6) imatinib-teva (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). 7) imatinib-teva (imatinib) is indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) 8) imatinib-teva (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist. 9) imatinib-teva (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - imatinib 400 mg - 400 mg